KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Depreciation and Depletion (2018 - 2025)

Biogen (BIIB) has 8 years of Depreciation and Depletion data on record, last reported at $68.0 million in Q4 2025.

  • For Q4 2025, Depreciation and Depletion fell 6.59% year-over-year to $68.0 million; the TTM value through Dec 2025 reached $272.8 million, down 4.85%, while the annual FY2025 figure was $272.8 million, 4.85% down from the prior year.
  • Depreciation and Depletion reached $68.0 million in Q4 2025 per BIIB's latest filing, up from $66.5 million in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $76.3 million in Q1 2022 and bottomed at $48.8 million in Q1 2021.
  • Average Depreciation and Depletion over 5 years is $66.1 million, with a median of $66.6 million recorded in 2021.
  • Peak YoY movement for Depreciation and Depletion: surged 56.35% in 2022, then decreased 18.61% in 2023.
  • A 5-year view of Depreciation and Depletion shows it stood at $66.6 million in 2021, then dropped by 2.85% to $64.7 million in 2022, then dropped by 1.85% to $63.5 million in 2023, then grew by 14.65% to $72.8 million in 2024, then dropped by 6.59% to $68.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation and Depletion were $68.0 million in Q4 2025, $66.5 million in Q3 2025, and $66.9 million in Q2 2025.